SCHEMBL128579

SCHEMBL128579

CSc1nc(N)nc2[nH]ncc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.44
ADORA1 P30542 1/20 0.44
MAP3K5 Q99683 1/20 0.44
NUDT1 P36639 1/20 0.41
CDK2 P24941 2/20 0.40
RET P07949 1/20 0.39
PI4KA P42356 1/20 0.39
XDH P47989 1/20 0.39
LRRK2 Q5S007 1/20 0.39
PI4K2B Q8TCG2 1/20 0.39
PI4K2A Q9BTU6 1/20 0.39
PI4KB Q9UBF8 1/20 0.39
ALDH1A1 P00352 4/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PDPK1 O15530 1/20 0.36
CHEK1 O14757 2/20 0.35
AURKA O14965 1/20 0.35
HTT P42858 1/20 0.35
ACHE P22303 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6336544 0.80 CCNE1 (0.38) ADORA2ACDK2RETPI4KAXDH
SCHEMBL129645 0.79 PLK4 (0.46) CDK2ALDH1A1SMN1; SMN2PDPK1HTT
SCHEMBL130809 0.79 HTR2C (0.37) CDK2RETPI4KAXDHLRRK2
SCHEMBL129933 0.79 ALDH1A1 (0.36) CDK2RETPI4KAXDHLRRK2
SCHEMBL14570604 0.76 ADORA2A (0.47) ADORA2AADORA1NUDT1CDK2RET
SCHEMBL29487078 0.75 XDH (0.55) ADORA2AADORA1CDK2RETPI4KA
SCHEMBL1014920 0.75 XDH (0.55) ADORA2AADORA1CDK2RETPI4KA
SCHEMBL5068437 0.74 RET (0.55) CDK2RETPI4KAXDHLRRK2
SCHEMBL31706902 0.73 PDPK1 (0.58) ADORA2AADORA1CDK2RETPI4KA
SCHEMBL129637 0.73 PDPK1 (0.58) ADORA2AADORA1CDK2RETPI4KA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-20210401840-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2021-12-30 US disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 US disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 US disclosed
US-10220035-B2 Compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-03-05 US disclosed
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2018-04-26 US disclosed
US-9775841-B2 Compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2017-10-03 US disclosed
US-9775841-B2 Compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2017-10-03 US disclosed
US-20160318890-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2016-11-03 US disclosed
US-20150174131-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2015-06-25 US disclosed
US-9018375-B2 Substituted chromenes as kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2015-04-28 US disclosed
US-9018375-B2 Substituted chromenes as kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2015-04-28 US disclosed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 US disclosed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 US disclosed
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2012-11-15 US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 ADORA2A 1325/4885ADORA1 2939/4885MAP3K5 48/4885
US-20210401840-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB ADORA2A 1821/4885ADORA1 3736/4885MAP3K5 36/4885
US-20150174131-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB ADORA2A 1556/4885ADORA1 3388/4885MAP3K5 60/4885
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB ADORA2A 1821/4885ADORA1 3736/4885MAP3K5 36/4885
US-10220035-B2 Compounds as modulators of protein kinases PRKCA, PRKCH, PRKCE ADORA2A 1519/4885ADORA1 3504/4885MAP3K5 50/4885
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB ADORA2A 1821/4885ADORA1 3736/4885MAP3K5 36/4885
US-20140080827-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB ADORA2A 1556/4885ADORA1 3388/4885MAP3K5 60/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB ADORA2A 1556/4885ADORA1 3388/4885MAP3K5 60/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB ADORA2A 1556/4885ADORA1 3388/4885MAP3K5 60/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A ADORA2A 1129/4885ADORA1 1608/4885MAP3K5 39/4885
US-20160318890-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB ADORA2A 1556/4885ADORA1 3388/4885MAP3K5 60/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB ADORA2A 1556/4885ADORA1 3388/4885MAP3K5 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.